A Phase 3 interventional study of Cabozantinib and Placebo in Differentiated Thyroid Cancer, sponsored by Exelixis. Active, not recruiting at 164 sites in 25 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Exelixis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Thyroid Cancer, Papillary with a site in United States — 9 open to participants now, 18 under way, 1 of them phase 3. Thyroid Cancer, Papillary · United States.
Among the 75 studies in Thyroid Cancer, Papillary with a site in United States, this one is the 4th largest by enrollment of the 62 interventional ones that give a count, is one of 3 that started in 2018, is one of 2 in phase 3, reaches primary completion later than 0 of the 16 other live ones, and was the 52nd registered.
186 studies on the registry are indexed under Thyroid Cancer, Papillary; 51 are open to participants now.
Browse Thyroid Cancer, Papillary studies →9 of the 75 studies in Thyroid Cancer, Papillary with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Jochen Lorch · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 33 Thyroid Cancer, Papillary studies recruiting now, 20 (61%) set no upper age limit and 8 (24%) stop at 75 or younger; 15 take children under 18; 3 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 42 · Phase 3 2
First in 1977; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 187 is above the median of 41 across 114 interventional studies indexed under Thyroid Cancer, Papillary.
Median enrollment 25 across the 62 interventional studies, 41 across the 8 observational. Of the 54 that completed or were terminated, 29 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 75 have an industry lead sponsor. The 10 most frequent:
Exelixis is the lead sponsor of 57 studies on the registry; 11 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Exelixis has 3 studies filed under Thyroid Cancer, Papillary — fewer than ten, so there is no comparison to draw.
5 of the studies in Thyroid Cancer, Papillary with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06440850City of Hope Medical CenterVemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation | 2026-11-22 |
| NCT02650401Hoffmann-La RocheStudy Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | 2027-06-30 |
| NCT07545837Mayo ClinicHealth and Wellness Coaching to Improve Adherence to Healthy Habits and Treatment Plans in Papillary and Follicular Thyroid Cancer Survivors | 2027-06-30 |
| NCT04544111Memorial Sloan Kettering Cancer CenterPDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer | 2027-09-02 |
| NCT04759911M.D. Anderson Cancer CenterSelpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer | 2027-11-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 75 studies in Thyroid Cancer, Papillary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior vascular endothelial growth factor receptor (VEGFR)-Targeted therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
cabozantinib (60 mg) once daily orally (qd)
Drug: Cabozantinib
placebo once daily orally (qd)
Drug: Placebo
Tablets containing 60-mg or 20-mg cabozantinib once daily orally.
Also known as: XL184, Cabometyx®
Tablets containing placebo equivalent of 60-mg or 20-mg cabozantinib once daily orally.
Progression Free Survival (PFS)
Time to the earlier of either radiographic progressive disease (PD) or death from any cause.
Time frame: Up to approximately twenty months after the first subject is randomized. Time from randomization to the earlier of the following events: radiographic PD as determined by the blinded independent central review (BIRC) or death due to any cause.
Objective Response Rate (ORR)
Proportion of subjects with the best overall response of complete response (CR) or partial response (PR).
Time frame: Six months after 100 subjects are randomized. Time from randomization to best overall response of confirmed complete response (CR) or confirmed partial response (PR) per BIRC per RECIST 1.1.
| Milestone | Cabozantinib | Placebo |
|---|---|---|
| Started | 125 | 62 |
| Completed | 89 | 26 |
| Not completed | 36 | 36 |
| Withdrew: Adverse event | 8 | 1 |
| Withdrew: Radiographic progression | 14 | 29 |
| Withdrew: Clinical deterioration | 10 | 6 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
Time to the earlier of either radiographic progressive disease (PD) or death from any cause.
| months | Cabozantinib | Placebo |
|---|---|---|
| Progression Free Survival (PFS) | NA (5.7 to NA) | 1.9 (1.8 to 3.6) |
Proportion of subjects with the best overall response of complete response (CR) or partial response (PR).
| percentage of participants | Cabozantinib | Placebo |
|---|---|---|
| Objective Response Rate (ORR) | 15 (5.8 to 29.3) | 0 (0.0 to 14.8) |
Collected over 1 year, 8 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cabozantinib | 17/125 (13.6%) | 43/125 (34.4%) | 112/125 (89.6%) |
| Placebo | 14/62 (22.6%) | 18/62 (29%) | 32/62 (51.6%) |
| Event | Cabozantinib | Placebo |
|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/125 | 4/62 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 4/125 | 3/62 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 4/125 | 0/62 |
| DiarrhoeaGastrointestinal disorders | 4/125 | 0/62 |
| Thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/125 | 0/62 |
| HydrothoraxRespiratory, thoracic and mediastinal disorders | 0/125 | 1/62 |
| PainGeneral disorders | 1/125 | 1/62 |
| Oedema peripheralGeneral disorders | 1/125 | 1/62 |
| Pain in jawMusculoskeletal and connective tissue disorders | 0/125 | 1/62 |
| PneumoniaInfections and infestations | 2/125 | 1/62 |
| Event | Cabozantinib | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 69/125 | 2/62 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 59/125 | 0/62 |
| FatigueGeneral disorders | 41/125 | 5/62 |
| HypertensionVascular disorders | 37/125 | 3/62 |
| NauseaGastrointestinal disorders | 33/125 | 1/62 |
| Decreased appetiteMetabolism and nutrition disorders | 33/125 | 10/62 |
| Alanine aminotransferase increasedInvestigations | 32/125 | 1/62 |
| Aspartate aminotransferase increasedInvestigations | 32/125 | 1/62 |
| HypocalcaemiaMetabolism and nutrition disorders | 30/125 | 1/62 |
| Weight decreasedInvestigations | 25/125 | 3/62 |
| Age, Categorical(Participants) | Cabozantinib | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 62 | 29 | 91 |
| >=65 years | 63 | 33 | 96 |
| Age, Continuous(years) | Cabozantinib | Placebo | Total |
|---|---|---|---|
| Median | 65 (32 to 85) | 66 (37 to 81) | 66 (32 to 85) |
| Sex: Female, Male(Participants) | Cabozantinib | Placebo | Total |
|---|---|---|---|
| Female | 68 | 34 | 102 |
| Male | 57 | 28 | 85 |
| Ethnicity (NIH/OMB)(Participants) | Cabozantinib | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 21 | 6 | 27 |
| Not Hispanic or Latino | 95 | 53 | 148 |
| Unknown or Not Reported | 9 | 3 | 12 |
| Race (NIH/OMB)(Participants) | Cabozantinib | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 0 | 3 |
| Asian | 20 | 14 | 34 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 3 |
| White | 90 | 41 | 131 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 11 | 5 | 16 |
| Region of Enrollment(participants) | Cabozantinib | Placebo | Total |
|---|---|---|---|
| Hong Kong | 0 | 1 | 1 |
| United States | 10 | 9 | 19 |
| Czechia | 1 | 0 | 1 |
| Thailand | 2 | 1 | 3 |
| Russia | 8 | 3 | 11 |
| Austria | 4 | 0 | 4 |
| Netherlands | 1 | 1 | 2 |
| South Korea | 8 | 8 | 16 |
| Brazil | 11 | 4 | 15 |
| Poland | 9 | 4 | 13 |
| France | 8 | 3 | 11 |
| Croatia | 1 | 0 | 1 |
| Argentina | 1 | 0 | 1 |
| Romania | 3 | 1 | 4 |
| Hungary | 5 | 3 | 8 |
| United Kingdom | 4 | 3 | 7 |
| Spain | 10 | 9 | 19 |
| Canada | 3 | 0 | 3 |
| Belgium | 3 | 2 | 5 |
| Taiwan | 6 | 3 | 9 |
| Italy | 14 | 5 | 19 |
| Mexico | 3 | 0 | 3 |
| Israel | 3 | 0 | 3 |
| Australia | 5 | 1 | 6 |
| Germany | 2 | 1 | 3 |
| Receipt of prior lenvatinib(Participants) | Cabozantinib | Placebo | Total |
|---|---|---|---|
| Count of participants | 79 | 39 | 118 |
Showing the first 100 of 164 sites across 25 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2018 to primary completion in Aug 2020, 22 months.
Results were first posted in May 2023, 2 years 8 months after primary completion. A results delay was requested in May 2021.
Completion moved once since we started tracking on Sep 25, 2026: Jul 2026 → Jul 2027, on Oct 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabozantinib